期刊文献+

结直肠癌KRAS和NRAS及BRAF基因突变状态分析 被引量:7

Colorectal Cancer KRAS,NRAS and Mutated BRAF Gene Mutation Analysis
下载PDF
导出
摘要 目的检测结直肠癌组织KRAS、NRAS及BRAF基因突变状态,分析突变与临床特征的关系。方法收集结直肠癌手术切除或穿刺活检标本218例,提取DNA经探针扩增阻滞突变系统聚合酶链反应扩增后,检测KRAS、NRAS及BRAF基因的突变状态,分析结直肠癌组织中3个基因间突变的内在关系,并分析KRAS突变与临床特征的关系。结果 218例CRC中,KRAS基因突变率为37.6%(82/218);NRAS基因突变率为4.1%(9/218);BRAF突变率为3.7%(8/218),在136例KRAS野生型病例中NRAS与BRAF的突变频率为6.6%(9/136)和5.9%(8/136)。BRAF与KRAS、NRAS基因突变相互排斥。KRAS基因突变更倾向发生于Ⅲ~Ⅳ期(P=0.014)和淋巴结转移的患者(P=0.049),与年龄、性别、肿瘤部位、分化程度等病理特征无关(P>0.05)。NRAS和BRAF基因突变与病理特征无关(P>0.05)。结论结直肠癌患者的KRAS突变速率较高,KRAS突变与淋巴结转移和肿瘤进展相关。联合检测KRAS、NRAS及BRAF基因,能正确指导和选择抗EGFR单抗药,实现个体化治疗的目标。 Objective To detect colorectal cancer tissue KRAS, NRAS and mutated BRAF gene mutation status, the relations between the mutation and clinical characteristics. Method Collect colorectal cancer resec- tion or biopsy specimens of 218 cases, DNA extracted by the probe amplification system block mutations PCR amplification, detection of KRAS, NRAS and mutated BRAF gene mutation status, analysis between three genes mutated in colorectal cancer tissue intrinsic relations, and analyzes the relations between KRAS mutations and clinical characteristics. Results Of 218 cases of CRC, KRAS mutation rate was 37.6 % (82/218) ; NRAS mutation rate was 4.1% (9/218) ; BRAF mutation rate was 3.7% (8/218), in the 136 cases KRAS wild - type NRAS and BRAF mutation frequency was 6.6% (9/136) and 5.9% (8/136). BRAF with KRAS, NRAS mu- tation mutually exclusive. KRAS mutations are more likely occur in the Ⅲ -Ⅳ- stage(P = 0. 014) and pa- tients with lymph node metastasis(P = 0. 049), with age, sex, tumor location, degree of differentiation, and other pathological features irrelevant( P 〉 0.05). NRAS and mutated BRAF gene mutation has nothing to do with the pathological characteristics (P 〉 0.05). Conclusion Colorectal cancer patients with KRAS mutation rate is higher, KRAS mutations associated with lymph node metastasis and tumor progression. Combined detec- tion of KRAS, NRAS and mutated BRAF gene, can correct guidance and select EGFR sheet resistance, resis- tance to realize individualized target therapy in the true sense.
出处 《内蒙古医学杂志》 2017年第1期4-7,共4页 Inner Mongolia Medical Journal
基金 内蒙古自治区人民医院科研项目
关键词 结直肠癌 EGFR KRAS NRAS BRAF colorectal cancer EGFR KRAS. NRAS BRAF
  • 相关文献

参考文献2

二级参考文献17

  • 1Alberto Morán,Paloma Ortega,Carmen de Juan,Tamara Fernández-Marcelo,Cristina Frías,Andrés Sánchez-Pernaute,Antonio José Torres,Eduardo Díaz-Rubio,Pilar Iniesta,Manuel Benito.Differential colorectal carcinogenesis:Molecular basis and clinical relevance[J].World Journal of Gastrointestinal Oncology,2010,2(3):151-158. 被引量:5
  • 2Jemal A,Siegel R,Xu J,et al.Cancer statistics,2010[J].CA Cancer J Clin,2010,60(5):277-300. 被引量:1
  • 3De Roock W,Claes B,Bemasconi D,et al.Effects of KRAS,BRAF,NRAS,and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer:a retrospective consortium analysis[J].Lancet Oncol,2010,11(8):753-762. 被引量:1
  • 4Souliferes D,Greer W,Magliocco AM,et al.KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies[J].Curr Oncol,2010,17 Suppl 1:S31-S40. 被引量:1
  • 5Van Cutsem E,Kdhne CH,Ldng I,et al.Cetuximab plus irinotecan,fluorouracil,and leucovorin as first-line treatment for metastatic colorectal cancer:updated analysis of overall survival according to tumor KRAS and BRAF mutation status[J].J Clin 0ncol,2011,29(15):2011-2019. 被引量:1
  • 6Zlobec I,Vuong T,Hayashi S,et al.A simple and reproducible scoring system for EGFR in colorectal cancer:application to prognosis and prediction of response to preoperative brachytherapy[J].Br J Cancer,2007,96(5):793-800. 被引量:1
  • 7Baldus SE,Schaefer KL,Engers R,et al.Prevalence and heterogeneity of KRAS,BRAF,and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases[J].Clin Cancer Res,2010,16(3):790-799. 被引量:1
  • 8Riely GJ,Ladanyi M.KRAS mutations:an old oncogene becomes a new predictive biomarker[J].J Mol Diagn,2008,10(6):493-495. 被引量:1
  • 9Downward J.Targeting RAS signalling pathways in cancer therapy[J].Nat Rev Cancer,2003,3(1):11-22. 被引量:1
  • 10Di Nicolantonio F,Martini M,Molinari F,et al.Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer[J].J Clin Oncol,2008,26(35):5705-5712. 被引量:1

共引文献23

同被引文献40

引证文献7

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部